PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
34845259-0	2021	Computer aided designing of novel pyrrolopyridine derivatives as JAK1 inhibitors.	4-azaindole	34-49	Janus kinase 1	Homo sapiens	65-69
26288682-1	2015	Early hit to lead work on a pyrrolopyridine chemotype provided access to compounds with biochemical and cellular potency against Janus kinase 2 (JAK2).	4-azaindole	28-43	Janus kinase 2	Homo sapiens	129-143
26288682-1	2015	Early hit to lead work on a pyrrolopyridine chemotype provided access to compounds with biochemical and cellular potency against Janus kinase 2 (JAK2).	4-azaindole	28-43	Janus kinase 2	Homo sapiens	145-149
19892732-10	2009	Molecular modeling indicates that PD-118057 binds to a hydrophobic pocket formed by L646 of one hERG1 subunit and F619 of an adjacent subunit.	4-azaindole	84-88	potassium voltage-gated channel subfamily H member 2	Homo sapiens	96-101
17480064-0	2007	Pyrrolopyridine inhibitors of mitogen-activated protein kinase-activated protein kinase 2 (MK-2).	4-azaindole	0-15	MAPK activated protein kinase 2	Homo sapiens	30-89
17480064-0	2007	Pyrrolopyridine inhibitors of mitogen-activated protein kinase-activated protein kinase 2 (MK-2).	4-azaindole	0-15	MAPK activated protein kinase 2	Homo sapiens	91-95
14561090-0	2003	Design and synthesis of 4-azaindoles as inhibitors of p38 MAP kinase.	4-azaindole	24-36	mitogen-activated protein kinase 14	Homo sapiens	54-57
28727840-4	2017	All Fes inhibitors selectively inhibited the growth of Flt3-ITD+ AML cells, with IC50 values for diaminopyrimidine and pyrrolopyridine inhibitors ranging from 19 to 166 nM.	4-azaindole	119-134	fms related receptor tyrosine kinase 3	Homo sapiens	55-59
28727840-9	2017	The pyrrolopyridine compound also induced apoptotic responses in patient-derived Flt3-ITD+ AML bone marrow cells but not in normal bone marrow mononuclear cells.	4-azaindole	4-19	fms related receptor tyrosine kinase 3	Homo sapiens	81-85
27346791-0	2016	Synthesis and evaluation of a series of 4-azaindole-containing p21-activated kinase-1 inhibitors.	4-azaindole	40-51	p21 (RAC1) activated kinase 1	Mus musculus	63-85
27346791-1	2016	A series of 4-azaindole-containing p21-activated kinase-1 (PAK1) inhibitors was prepared with the goal of improving physicochemical properties relative to an indole starting point.	4-azaindole	12-23	p21 (RAC1) activated kinase 1	Mus musculus	35-57
27346791-1	2016	A series of 4-azaindole-containing p21-activated kinase-1 (PAK1) inhibitors was prepared with the goal of improving physicochemical properties relative to an indole starting point.	4-azaindole	12-23	p21 (RAC1) activated kinase 1	Mus musculus	59-63
27346791-4	2016	Structure-activity relationship studies around 5 identified additional 4-azaindole analogs with superior PAK1 biochemical activity (Ki <10nM) and up to 24-fold selectivity for group I over group II PAKs.	4-azaindole	71-82	p21 (RAC1) activated kinase 1	Mus musculus	105-109
22280316-4	2012	Here we incorporated the multispecies approach into the QM/MM linear response method and used it for structural correlation of published inhibition data on mitogen-activated protein kinase (MAPK)-activated protein kinase (MK2) by 66 benzothiophene and pyrrolopyridine analogues, forming up to five tautomers and seven ionization species under experimental conditions.	4-azaindole	252-267	MAPK activated protein kinase 2	Homo sapiens	222-225
21613416-4	2011	Treatment with protein kinase inhibitors specific for both MK-2 (C23, a pyrrolopyridine-type compound) or p38 MAPK (SB203580) reduced PAN-induced podocyte injury and actin cytoskeletal disruption.	4-azaindole	72-87	MAPK activated protein kinase 2	Homo sapiens	59-63
19394223-1	2009	Exploration of the SAR around a series of 3,5-disubstituted-1H-pyrrolo[2,3-b]pyridines led to the discovery of novel pyrrolopyridine inhibitors of the IGF-1R tyrosine kinase.	4-azaindole	117-132	sarcosine dehydrogenase	Homo sapiens	19-22
19394223-1	2009	Exploration of the SAR around a series of 3,5-disubstituted-1H-pyrrolo[2,3-b]pyridines led to the discovery of novel pyrrolopyridine inhibitors of the IGF-1R tyrosine kinase.	4-azaindole	117-132	insulin like growth factor 1 receptor	Homo sapiens	151-157
19369077-0	2009	Discovery of 4-azaindoles as novel inhibitors of c-Met kinase.	4-azaindole	13-25	MET proto-oncogene, receptor tyrosine kinase	Homo sapiens	49-54
19369077-1	2009	A series of 4-azaindole inhibitors of c-Met kinase is described.	4-azaindole	12-23	MET proto-oncogene, receptor tyrosine kinase	Homo sapiens	38-43
34845259-5	2021	In this study, we used computational methods on a series of pyrrolopyridine derivatives to design new JAK1 inhibitors.	4-azaindole	60-75	Janus kinase 1	Homo sapiens	102-106
30388009-0	2019	C-H Arylation in the Formation of a Complex Pyrrolopyridine, the Commercial Synthesis of the Potent JAK2 Inhibitor, BMS-911543.	4-azaindole	44-59	Janus kinase 2	Homo sapiens	100-104
34293041-0	2021	A highly potent and safe pyrrolopyridine-based allosteric HIV-1 integrase inhibitor targeting host LEDGF/p75-integrase interaction site.	4-azaindole	25-40	integrase	None	64-73
34293041-0	2021	A highly potent and safe pyrrolopyridine-based allosteric HIV-1 integrase inhibitor targeting host LEDGF/p75-integrase interaction site.	4-azaindole	25-40	PC4 and SFRS1 interacting protein 1	Homo sapiens	99-108
33504139-5	2021	We demonstrate here, using pre-clinical and clinical correlative studies, that the novel 4-azaindole derivative, PLX51107, has BET-inhibitory activity in vitro and in vivo.	4-azaindole	89-100	delta/notch like EGF repeat containing	Homo sapiens	127-130
31829554-5	2020	Using the receptor tyrosine kinase (RTK) discoidin domain receptor 1 (DDR1) as a proof-of-concept target in a droplet-scale competition binding assay, we screened a 67,100-member solid-phase DEL of drug-like small molecules for competitive ligands of DDR1 and identified several known RTK inhibitor pharmacophores, including azaindole- and quinazolinone-containing monomers.	4-azaindole	325-334	ret proto-oncogene	Homo sapiens	10-34
31829554-5	2020	Using the receptor tyrosine kinase (RTK) discoidin domain receptor 1 (DDR1) as a proof-of-concept target in a droplet-scale competition binding assay, we screened a 67,100-member solid-phase DEL of drug-like small molecules for competitive ligands of DDR1 and identified several known RTK inhibitor pharmacophores, including azaindole- and quinazolinone-containing monomers.	4-azaindole	325-334	ret proto-oncogene	Homo sapiens	36-39
31829554-5	2020	Using the receptor tyrosine kinase (RTK) discoidin domain receptor 1 (DDR1) as a proof-of-concept target in a droplet-scale competition binding assay, we screened a 67,100-member solid-phase DEL of drug-like small molecules for competitive ligands of DDR1 and identified several known RTK inhibitor pharmacophores, including azaindole- and quinazolinone-containing monomers.	4-azaindole	325-334	discoidin domain receptor tyrosine kinase 1	Homo sapiens	70-74
31590280-0	2019	Solvent-Free C-3 Coupling of Azaindoles with Cyclic Imines.	4-azaindole	29-39	complement C3	Homo sapiens	13-16
33218895-3	2021	We present here a new series of pyrazolopyridine and pyrrolopyridine derivatives as HNE inhibitors designed as modifications of our previously synthesized indazoles and indoles in order to evaluate effects of the change in position of the nitrogen and/or the insertion of an additional nitrogen in the scaffolds on biological activity and chemical stability.	4-azaindole	53-68	elastase, neutrophil expressed	Homo sapiens	84-87
30388009-1	2019	The development of an improved short and efficient commercial synthesis of the JAK2 inhibitor, a complex pyrrolopyridine, BMS-911543, is described.	4-azaindole	105-120	Janus kinase 2	Homo sapiens	79-83
30891123-1	2019	Herein, we disclose a series of selective GluN2B negative allosteric modulators containing a 1H-pyrrolo[3,2-b]pyridine core.	4-azaindole	93-118	glutamate ionotropic receptor NMDA type subunit 2B	Rattus norvegicus	42-48
30148035-0	2018	In silico insights into prediction and analysis of potential novel pyrrolopyridine analogs against human MAPKAPK-2: a new SAR-based hierarchical clustering approach.	4-azaindole	67-82	MAPK activated protein kinase 2	Homo sapiens	105-114
30148035-1	2018	In the present study, we have focused on to elucidate potential bioactive pyrrolopyridine (PYP23) analogs against human mitogen-activated protein kinase-activated protein kinase-2 (MK-2).	4-azaindole	74-89	MAPK activated protein kinase 2	Homo sapiens	120-179
30148035-1	2018	In the present study, we have focused on to elucidate potential bioactive pyrrolopyridine (PYP23) analogs against human mitogen-activated protein kinase-activated protein kinase-2 (MK-2).	4-azaindole	74-89	MAPK activated protein kinase 2	Homo sapiens	181-185